Ligandal is developing pepitide-mimetic vaccines that can trigger T cell and B cell responses to the novel coronavirus, while also serving as competitive inhibitors and drug/gene delivery carriers to target the ACE2 receptor.

Ligandal

San Francisco

Ligandal startup from San Francisco, United States is ranked null out of 2449 worldwide and null from the 748 startups in United States. See more information and additional rankings on the StartupBlink Global Ecosystem Map